Firazyr meets HAE endpoint

Shire plc (LSE:SHP; NASDAQ:SHPGY) said subcutaneous Firazyr icatibant met the primary endpoint in the Phase III FAST-3 trial to treat acute attacks of hereditary angioedema (HAE). The selective peptidomimetic bradykinin B2 receptor antagonist significantly reduced the median time to onset of symptom relief for the first attack after enrollment as measured by a 50% reduction in a composite symptom score assessed by the patient vs. placebo (2 vs. 19.8 hours, p<0.001). The double-blind, international trial enrolled 88 patients with moderate to very severe cutaneous and/or abdominal symptoms. ...